Establishment and characterization of a cell based artificial antigen-presenting cell for expansion and activation of CD8+ T cells ex vivo

Cellular and Molecular Immunology

Volumn 5, Issue 1, 2008, Pages 47-53

  Gong, Weijuan ^a   Ji, Mingchun ^a   Cao, Zhengfeng ^a   Wang, Liheng ^a   Qian, Yayun ^a   Hu, Maozhi ^a   Qian, Li ^a   Pan, Xingyuan ^a  

^a YANGZHOU UNIVERSITY   (China)

Author keywords

4 1BBL; activation; artificial antigen presenting cell; CD86; expansion

Indexed keywords

CD137 ANTIGEN; CD137 LIGAND; CD28 ANTIGEN; CD3 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; PERFORIN; TNFRSF9 PROTEIN, HUMAN;

ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL STRAIN K 562; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MONONUCLEAR CELL;

4-1BB LIGAND; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD137; ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, CD86; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; HUMANS; INTERFERON TYPE II; K562 CELLS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; PERFORIN;

EID: 47049104090     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2008.6     Document Type: Article

References (30)

1. Kim JV, Latouche JB, Riviere I, Sadelain M. The ABCs of artificial antigen presentation. Nat Biotechnol. 2004;22:403-410. (Pubitemid 38451370)
2. Oelke M, Krueger C, Giuntoli RL, Schneck JP. Artificial antigen-presenting cells: artificial solutions for real diseases. Trends Mol Med. 2005;11:412-420. (Pubitemid 41254044)
3. Maus MV, Thomas AK, Leonard DG, et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol. 2002;20:143-148. (Pubitemid 34158029)
4. Butler MO, Lee JS, Ansen S, et al. Long-lived antitumor CD8+ T lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res. 2007;13:1857-1867. (Pubitemid 46952956)
5. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2:116-126. (Pubitemid 37323235)
6. Sansom DM, Manzotti CN, Zheng Y. Whats the difference between CD80 and CD86? Trends Immunol. 2003;24:313-318.
7. Bhatia S, Edidin M, Almob SC, Nathenson SG. B7-1 and B7-2: Similar costimulatory ligands with different biochemical, oligomeric and signaling properties. Immunol Letters. 2006; 104:70-75. (Pubitemid 43330711)
8. Brooks DG, Qiu WQ, Luster AD, Ravetch JV. Structure and expression of human IgG FcRII (CD32). Functional heterogeneity is encoded by the alternatively spliced products of multiple genes. J Exp Med. 1989;170:1369-1385. (Pubitemid 19250700)
9. Van Sorge NM, Van der Pol WL, Van de Winkel JGJ. FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens. 2003;61:189-202. (Pubitemid 36605541)
10. Altman JD, Moss PAH, Goulder PJR, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94-96. (Pubitemid 26332731)
11. Thomas AK, Maus MV, Shalaby WS, June CH, Riley JL. A cellbased artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clin Immunol. 2002;105:259-272. (Pubitemid 36016053)
12. Sasawatari S, Tadaki T, Isogai M, Takahara M, Nieda M, Kakimi K. Efficient priming and expansion of antigen-specific CD8+ T cells by a novel cell-based artificial APC. Immunol Cell Biol. 2006;84:512-521. (Pubitemid 44657023)
13. Suhoski MM, Golovina TN, Aqui NA, et al. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther. 2007;15:981-988. (Pubitemid 46621657)
14. Wolfers J, Lozier A, Raposo G, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL crosspriming. Nat Med. 2001;7:297-303. (Pubitemid 32224344)
15. Derdak SV, Kueng HJ, Leb VM, et al. Direct stimulation of T lymphocytes by immunosomes: Virus-like particles decorated with T cell receptor/CD3 ligands plus cotimulatory molecules. Proc Natl Acad Sci U S A. 2006;103:13144-13149. (Pubitemid 44338930)
16. Sun S, Cai Z, Langlade-Demoyen P, et al. Dual function of Drosophila cells as APCs for naive CD8+ T cells: implications for tumor immunotherapy. Immunity. 1996;4:555-564. (Pubitemid 26233309)
17. Janetzki S, Song P, Gupta V, Lewis JJ, Houghton AN. Insect cells as HLA-restricted antigen-presenting cells for the IFN-γ elispot assay. J Immunol Methods. 2000;234:1-12. (Pubitemid 30084793)
18. Latouche JB, Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol. 2000;18:405-409. (Pubitemid 30217527)
19. Papanicolaou GA, Latouche JB, Tan C, et al. Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele. Blood. 2003;102:2498-2505. (Pubitemid 37193588)
20. Dupont J, Latouche JB, Ma C, Sadelain M. Artificial antigenpresenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res. 2005;65:5417-5427. (Pubitemid 40827355)
21. Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med. 2003;9:619-624. (Pubitemid 36597110)
22. Maus MV, Riley JL, Kwok WW, Neopm GT, June CH. HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells. Clin Immunl. 2003;106:16-22. (Pubitemid 36263297)
23. Oosten LE, Blokland E, van Halteren AG, et al. Artificial antigen-presenting constructs efficiently stimulate minor histocompatibility antigen-specific cytotoxic T lymphocytes. Blood. 2004;104:224-226. (Pubitemid 38879861)
24. Schilbach K, Kerst G, Walter S, et al. Cytotoxic minor histocompatibility antigen HA-1-specific CD8+ effector memory T cells: artificial APCs pave the way for clinical application by potent primary in vitro induction. Blood. 2005;106:144-149. (Pubitemid 40967186)
25. Prakken B, Wauben M, Genini D, et al. Artificial antigenpresenting cells as a tool to exploit the immune synapse. Nat Med. 2000;6:1406-1410. (Pubitemid 32001028)
26. Giannoni F, Barnett J, Bi K, et al. Clustering of T cell ligands on artificial APC membranes influences T cell activation and protein kinase Cθ translocation to the T cell plasma membrane. J Immunol. 2005;174:3204-3211. (Pubitemid 40354022)
27. Lohr J, Knoechel B, Jiang S, Sharpe AH, Abbas AK. The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat Immunol. 2003;4:664-669. (Pubitemid 36874443)
28. Cheuk AT, Mufti GJ, Guinn B. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther. 2004;11:215-226. (Pubitemid 38280524)
29. Nam KO, Kang WJ, Kwon BS, Kim SJ, Lee HW. The therapeutic potential of 4-1BB (CD137) in cancer. Curr Cancer Drug Targets. 2005;5:357-363. (Pubitemid 41097759)
30. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003;9:279-286. (Pubitemid 36362782)